WO2005026138A1 - 2−ナフチルイミノ−1,3−チアジン誘導体 - Google Patents
2−ナフチルイミノ−1,3−チアジン誘導体 Download PDFInfo
- Publication number
- WO2005026138A1 WO2005026138A1 PCT/JP2004/012086 JP2004012086W WO2005026138A1 WO 2005026138 A1 WO2005026138 A1 WO 2005026138A1 JP 2004012086 W JP2004012086 W JP 2004012086W WO 2005026138 A1 WO2005026138 A1 WO 2005026138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- optionally substituted
- acceptable salt
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
Definitions
- the present invention relates to a 2-naphthylimino-1,3-thiazine derivative having a cannapinoid receptor agonist action and a pharmaceutical use thereof.
- Cannabinoids were discovered as the active substance of marijuana in 1960, and its actions are central nervous system effects (hallucinations, euphoria, disruption of spatiotemporal sensation, etc.) and peripheral cell system effects (immunosuppressive effects). , Anti-inflammatory, analgesic effects, etc.).
- Non-Patent Document 1 reports the effect of anandamide on cardiovascular.
- a cannapinoid receptor a cannapinoid type 1 receptor was discovered in 1990 and was found to be distributed in the central nervous system such as the brain, and its agonists suppressed the release of neurotransmitters and exhibited central effects such as hallucinations. I'm sorry.
- Non-Patent Document 2 discloses that Cannapinoid receptor agonist ⁇ 9 -tetrahydrocannabinol and the like have a bronchodilator effect. Further, Patent Document 1 discloses that a cannapinoid receptor agonist has an antipruritic effect.
- Patent Document 2 isoindolinone derivatives (Patent Document 2), pyrazole derivatives (Patent Document 3), quinolone derivatives (Patent Documents 4 and 5), pyridone derivatives (Patent Document 6), thiazine derivatives ( Patent Documents 7 and 8) are known.
- Patent Document 1 WO 03/035109 pamphlet
- Patent Document 2 International Publication No.
- Patent Document 3 WO 98/41519 pamphlet
- Patent Document 4 WO 99/02499 pamphlet
- Patent Document 5 WO 00/40562 pamphlet
- Patent Document 6 International Publication No. 02/053543 Pamphlet
- Patent Document 7 International Publication No. 01/19807 pamphlet
- Patent Document 8 International Publication No. 02/072562 pamphlet
- Non-Patent Document 1 Hypertension 1997, Vol. 29, p. 1204-121 0
- Non-Patent Document 2 Nature, 1993, Vol. 365, p. 61-65
- Non-Patent Document 3 Ioumal of Cannabi's Therapeutics, 2002, Vol. 1, No. 59, p. 59-71
- a compound having a cannabinoid receptor agonist action and a pharmaceutical composition containing the compound as an active ingredient are created, and an analgesic, a pain remedy, an antipruritic, or a bronchodilator is provided.
- the present inventors have found that the 2_naphthylimino 1,3_thiazine derivative shown below has a strong cannabinoid receptor agonist action, and that an analgesic, a pain remedy containing them as an active ingredient, It has been found that it is effective as an antipruritic or a bronchodilator.
- R 3 are the same or different and C2-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy C1-C4 alkyl, optionally substituted amino C1-C4 alkyl or C3-C6 cycloalkyl C1 —C4 alkyl; or R 2 and R 3 together with adjacent carbon atoms may be substituted, substituted or unsubstituted 5 to 8 membered non-aromatic carbocyclic ring or optionally substituted 5 to 8 membered non-aromatic heterocycle May form a ring;
- R 4 is CI—C6 alkyl, hydroxy CI—C6 alkyl, optionally substituted amino C1-C6 alkyl, or C1-C6 alkoxy C1-C6 alkynole;
- X is an oxygen atom or a sulfur atom
- A is the formula:
- W may be (substituted, substituted, heteroatom) intervening, C2_C6 alkylene or (substituted, substituted, heteroatom) intervening, C2 —C4 alkenylene); n is an integer of 0-7), a pharmaceutically acceptable salt thereof, or a solvate thereof.
- R 1 is the same or different and is alkyl, alkoxy, optionally substituted amino, halogen, hydroxy, haloalkyl, haloalkoxy, cyano, or alkoxy carbonylcarbonyl);
- R 2 and R 3 are the same or different and are C2-C4 alkyl; or
- R 2 and R 3 may be taken together with adjacent carbon atoms to form a 5- or 6-membered cycloalkane
- R 4 is C1-C6 alkyl
- X is an oxygen atom or a sulfur atom
- n is an integer of 0-7), a pharmaceutically acceptable salt thereof, or a solvate thereof.
- R 1 is the same or different and is an alkyl, alkoxy, optionally substituted halogen atom, hydroxy, haloalkyl, haloalkoxy, cyano, or alkoxy force; norlevoni / leanoreoxy;
- R 2 and R 3 are the same or different and are C2-C4 alkyl; or
- R 2 and R 3 may be taken together with adjacent carbon atoms to form a 5- or 6-membered cycloalkane
- R 4 is C1-C6 alkyl
- X is an oxygen atom or a sulfur atom
- n is an integer of 0 to 3
- a pharmaceutically acceptable salt thereof or a solvate thereof.
- R 4 force The compound according to 1) or 12), which is S methyl or ethyl, the pharmaceutically acceptable salt or a solvate thereof.
- a pharmaceutical composition comprising the compound according to any of 1) to 13), a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.
- a pharmaceutical composition comprising, as an active ingredient, the compound described in 1) to 13) above, which is a cannapinoid receptor agonist, a pharmaceutically acceptable salt thereof, or a solvate thereof.
- a method for treating a disease associated with a cannapinoid receptor which comprises administering the compound according to any of 1) to 13), a pharmaceutically acceptable salt thereof, or a solvate thereof.
- Halogen atom means a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- Hetero atoms include nitrogen, oxygen and sulfur atoms.
- alkynole includes linear or branched alkyl having 1 to 10 carbon atoms, and includes, for example, methinole, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butynole , N-pentinole, isopentinole, neo_pentinole, n_hexinole, n-heptinole, n-otatyl, n-noninole, n-decyl and the like.
- straight-chain or branched alkyl having 1 to 4 carbon atoms is preferred.
- methinole ethyl, n-propyl, isopropyline, n-butyl, isobutyl, sec-butyl and t_butyl are preferred. I like it.
- the number of carbon atoms when specified, it means “alkyl” having the number of carbon atoms in the range.
- Cycloalkylalkyl includes the above “alkyl” substituted by at least one of the following “cycloalkyl”, and includes, for example, cyclopropinolemethinole, 2-cyclopentylethyl, 2-cyclopentylethyl Chlohexylethyl, 2-cyclohexylpropyl and the like.
- Haldroxyalkyl includes the above “alkyl” substituted by one or more “hydroxy”, and includes, for example, 2-hydroxyethyl, 3-hydroxypropyl and the like.
- alkoxyalkyl includes the above “alkyl” substituted by one or more of the following “alkoxy”, and includes, for example, methoxymethinole, 2-methoxyethyl, 2-ethoxysethyl, 3-methoxypropyl and the like.
- Alkylthioalkyl includes the above “alkynole” substituted with one or more of the following “alkylthio”, and includes, for example, methylthiomethyl, 2-methylthioethyl, 2-ethylthioethyl, 3-methylthiopropyl and the like.
- ⁇ substituted or substituted, aminoanolequinole '' includes the above-mentioned ⁇ alkyl '' substituted by one or more of the following ⁇ substituted, substituted or substituted, amino '', for example, Methinoleaminomethinole, 2-dimethylaminoaminoethyl, 2-getylaminoethyl, 3-dimethylaminopropyl, etc.
- Alkoxyiminoalkyl includes the above “alkyl” substituted by one or more imino groups substituted with the following “alkoxy”, for example, methoxyiminomethyl, 2-methoxyiminoethyl, 2_ethoxyimino Ethyl, 2-methoxyiminopropyl and the like.
- alkenyl includes a linear or branched alkenyl having 2 to 8 carbon atoms having one or more double bonds in the above “alkyl”, for example, vinyl, 1-propyl
- alkyl for example, vinyl, 1-propyl
- Examples include quinole, arylinole, isopropenyl, 1-butul, 2-butul, 3-butenyl, 2-pentenyl, 1,3-butagenyl, 3-methyl-2-butenyl and the like.
- straight-chain or branched alkenyl having 2 to 4 carbon atoms is preferred, and specifically, aryl, isopropyl, and 3-butenyl are preferred.
- the number of carbon atoms is specified, it means “alkenyl” having the number of carbon atoms within the range.
- alkynyl includes a linear or branched alkynyl having 2 to 8 carbon atoms having one or more triple bonds in the above “alkyl” and includes, for example, ethur, propargyl and the like. Can be Particularly, a straight-chain or branched alkynyl having 24 carbon atoms is preferable, and specifically, propargyl is preferable.
- Haloalkyl means a group in which the above “alkyl” is substituted with one or more halogens, For example, chloromethinole, dichloromethinole, diphnoleolomethinole, triphneolelomethinole, chloroethyl (for example, 2_chloroethyl), dichloroethyl (for example, 1,2-dichloroethylene, 2,2-dichloroethyl) And propyl chloro (for example, 2-chloro propylinole, 3-chloro propyl and the like) and the like. C1-C3 haloalkyl is preferred.
- C2-C6 alkylene, which may be intervened (substituted, substituted, or heteroatom) refers to a group in which 1 to 3 heteroatoms may be substituted by alkyl. And straight-chain or branched alkylene having 2 to 6 carbon atoms.
- substituents include the above-mentioned “alkyl”, the following “aralkyl”, the following “aryl”, the following “heteroaryl”, the following “acryl”, and the following “alkoxycarbonyl”.
- alkyl the following “aralkyl”
- aryl the following “heteroaryl”
- acryl the following “alkoxycarbonyl”.
- alkoxycarbonyl alkoxycarbonyl
- C2_C4 alkenylene may intervene means that it may be substituted by alkyl even if it has 1 to 2 heteroatoms. Includes linear or branched alkenylene having good carbon number of 2-4. Examples of the substituent include the above-mentioned “alkyl”, the following “aralkyl”, the following “aryl”, the following “heteroaryl”, the following “acryl”, the following “alkoxycarbonyl”, and the like.
- the “cycloalkane” includes cycloalkanes having 310 carbon atoms, and includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane and the like. Preferably, it is a cycloalkane having 58 carbon atoms, for example, cyclopentane, cyclohexane, cycloheptane, cyclooctane. In particular, when the number of carbon atoms is specified, it means "cycloalkane" having members in that number range.
- Carbocycle includes a carbocycle having 3 to 10 members which may have one or more double bonds and / or triple bonds, for example, cyclopropane, cyclobutane, cyclopentane, cyclopentene, Examples include cyclohexane, cyclohexene, cycloheptane, cycloheptene, cyclooctene and the like. Preferably, it is a cycloalkane having 5 to 8 carbon atoms, and examples thereof include cyclopentane, cyclohexane, cycloheptane, and cyclooctane. In particular, when a carbon number is specified, it means a “carbocycle” having members in the range of the number.
- Non-aromatic carbocycle includes a 3- to 10-membered non-aromatic carbocycle which may have one or more double bonds and / or triple bonds, for example, cyclopropane, cyclobutane, Pentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane, cycloheptene, cyclootaten and the like.
- it is a cycloalkane having 5 to 8 carbon atoms, for example, cyclopentane, cyclohexane, cycloheptane and cyclooctane.
- the number of carbon atoms is specified, it means a "non-aromatic carbon ring" having members in that number range.
- the “cycloalkyl” includes cycloalkyl having 3 to 10 carbon atoms, and includes, for example, cyclopropynole, cyclopentinole, cyclopentinole, cyclohexinole, cycloheptinole, cyclooctyl and the like.
- it is a cycloalkyl having 3 to 6 carbon atoms, and examples thereof include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- the number of carbon atoms is specified, it means "cycloalkyl" having the number of carbon atoms in the range.
- aryl includes aryl having 6 to 14 carbon atoms, and examples thereof include phenyl, naphthyl, anthryl, and phenanthryl. Particularly, phenyl and naphthyl are preferred.
- aranolequinole includes a group in which the above “alkyl” is substituted by the above “aryl”.
- aryl e.g., benzyl, phenylethyl (eg, 1-phenylethyl, 2_phenylethyl), phenylpropyl (eg, 1-phenylethyl) —Phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, etc.), naphthylmethyl (eg, 1_naphthylmethyl, 2_naphthylmethyl) and the like. Particularly, benzyl and naphthylmethyl are preferred.
- Heteroaryl includes heteroaryl having 119 carbon atoms containing 114 nitrogen atoms, oxygen atoms and / or sulfur atoms, and is, for example, furyl (for example, 2_furyl, 3-furyl). ), Phenyl (eg, 2-phenyl, 3-phenyl), pyrrolyl (eg, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (eg, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl) , Pyrazolyl (eg, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolinole (eg, 1,2,4_triazol-1_yl, 1,2,4-triazolyl-3-yl, 1, 2,4-triazol-4-yl), tetrazolyl (eg, 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazo
- the ⁇ non-aromatic heterocyclic group '' includes a nitrogen atom, an oxygen atom, and a non-aromatic cyclic group having 1 to 9 carbon atoms containing 1 to 4 Z or sulfur atoms, for example, 1_ pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidino, 2-pyrrolidinyl, 3-pyrrolidinyl, piperidino, 2-piperidyl, 3-piperidyl, 4-piperidyl, piperazino, 2-piperazul, 2_monorefolininole, 3-monoleolininole, monoreholino , Tetrahydropyranyl and the like. Particularly, monoreholino, pyrrolidino, piperidino, and piperazino are preferred.
- non-aromatic heterocycle includes a nitrogen atom, an oxygen atom, and a non-aromatic ring having 119 carbon atoms containing 14 Z or sulfur atoms, such as tetrahydrofuran, tetrahydrothiophene, Pyrrolidine, tetrahydropyran, piperidine, morpholine and the like can be mentioned. Particularly, tetrahydropyran and piperidine are preferable.
- alkyl part of “alkoxy” has the same meaning as the above “alkyl”.
- Alkoxy includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, n-octyloxy and the like.
- methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and t-butoxy which are preferred by alkoxy having 14 carbon atoms, are mentioned.
- the number of carbon atoms is specified, it means “alkoxy” having the number of carbon atoms within the range.
- Haloalkoxy means a group in which the above “alkoxy” has been substituted by one or more halogens, for example, dichloromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy (2, 2, 2 _ Trifluoroethoxy) and the like. Particularly, difluoromethoxy and trifluoromethoxy are preferable.
- Aryloxy includes a group in which one of the above “aryl” is substituted on an oxygen atom, for example, phenoxy, naphthoxy (eg, 11-naphthoxy, 2_naphthoxy, etc.), anthrinoleo Xy (for example, 1-anthroxy, 2-anthroxy) and phenanthroxy (for example, 1-phenanthroxy, 2-phenanthroxy, etc.). Particularly, phenoxy and naphthoxy are preferred.
- Alkyloxy includes a group in which one of the above “aralkyl” is substituted on an oxygen atom, and examples include benzyloxy, phenethyloxy and the like. Particularly, benzyloxy is preferable.
- Alkoxyalkoxy includes the above “alkoxy” substituted with the above “alkoxy”, for example, methoxymethoxy, ethoxymethoxy, n-propoxymethoxy, isopropoxymethoxy, 1-methoxyethoxy, 2-methoxyethoxy And the like.
- 1-methoxyethoxy and 2-methoxyethoxy are preferred.
- Alkylthioalkoxy includes the above “alkoxy” substituted with the following “alkylthio”, such as methylthiomethoxy, ethylthiomethoxy, n-propylthiomethoxy, isopropylthiomethoxy, 1-methylthioethoxy, 2-methylthioethoxy and the like. Particularly, 1-methylthioethoxy and 2-methylthioethoxy are preferred.
- Carboxyalkoxy includes the above “alkoxy” substituted by one or more “carboxy”, and includes, for example, carboxymethoxy, 2-carboxyethoxy and the like.
- Alkoxycarbonylalkoxy means a group in which the above “alkoxy” is substituted by the following “alkoxycarbonyl", for example, methoxycarbonylmethoxy, ethoxycarbonylmethoxy, n-propoxycarbonylmethoxy, i-propoxycarbonylmethoxy, n -Butoxycarbonylmethoxy, i-butoxycarbonylmethoxy, sec-butoxycarbonylmethoxy, tert-butoxycarbonylmethoxy, 2_ (tert-butoxycarbonyl) ethoxy, 2_ (n-pentylcarboxycarbonyl) ethoxy, 2- (n-hexyloxycarbonyl) ethoxy, n-heptyloxycarbonylmethoxy, n-octyloxycarbonylmethoxy and the like. Particularly, tert-butoxycarbonylmethoxy and 2_ (tert-butoxycarbonyl)
- cyanoalkoxy includes the above “alkoxy” substituted by one or more “cyano”, and includes, for example, cyanomethoxy, 2-cyanoethoxy and the like.
- alkyl part of “alkylthio” has the same meaning as the above “alkyl”.
- Alkyl Examples of "o” include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, t-butylthio, n-pentylthio, n-hexylthio and the like.
- methylthio, ethylthio, n-propylthio, isopropylthio, n_butylthio, isobutylthio, sec-butylthio, and t-butylthio which are preferably straight-chain or branched alkylthio having 14 carbon atoms.
- “Amino which may be substituted” includes unsubstituted amino group CI—C4 anolequinoleamino, (C1—C4 alkyl) carbonylamino, arylcarbonylamino, N_ (C1_C4 alkyl) carbonyl C1—C4 Alkylamino, aralkylamino, C1-C4 alkylsulfonylamino, C2-C4alkenyloxycarbonylamino, (C1-C4alkoxy) carbonylamino, C2-C4alkenylamino, arylcarbonylamino, and heteroarylcarbonylamino No.
- unsubstituted C1-C4 anolequinoleamino, (C1-C4 alkyl) carbonylamino, and (C1-C4 alkoxy) carbonylamino are preferred.
- the CI-C4 alkylamino includes, for example, methylamino, ethylamino, n-propylamino, i-propylamino, dimethylamino, getylamino, ethylmethylamino, and propylmethylamino.
- the (C1-C4 alkyl) carbonylamino includes, for example, honolemilamino and acetylionamino with acetylamino. Examples of arylcarbonyl include, for example, benzoylamino.
- the N_ (C1_C4 alkyl) carbonylalkylamino includes, for example, N-acetylmethylamino.
- Examples of the aranolekilamino include benzylamino, 1-phenylethylamino, 2-phenylethylamino, 1-phenylpropynoleamino, 2phenylphenylamino, and 3phenylphenylamino. , 1_naphthylmethylamino, 2_naphthylmethylamino, and dibenzylamino.
- Examples of the C1-C4 alkyls-sulfonylamino include methanesulfonylamino and ethanesulfonylamino.
- the C2-C4 alkenyloxycarbonylamino includes, for example, buroxycarboninoleamino and aryloxycarbonylamino.
- (C1-C4 alkoxy) carboninoleamino includes, for example, methoxycarbonylamino, ethoxycarbonylamino, tert-butoxycarbonylamino.
- the C2-C4 alkenylamino includes, for example, butylaminoarylamino.
- the arylcarbonylamino includes, for example, benzoylamino.
- Heteroarylcarbonylamino is, for example, pyridinecarbonyl Lumino.
- acyl refers to a carbonyl group substituted with a group other than hydrogen, such as alkylcarbonyl (eg, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, otanoyl, lauroyl, etc.).
- alkylcarbonyl eg, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, otanoyl, lauroyl, etc.
- Alkenylcarbonyl for example, atariloinole, metaatariloyl
- cycloalkylcarbonyl for example, cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, etc.
- arylcarbonyl benzoyl, naphthoyl, etc.
- Heteroarylcarbonyl pyridylcarbonyl, etc. power S.
- These groups may be further substituted with substituents such as alkyl and halogen.
- an alkylcarbonyl-substituted arylcarbonyl includes a toluoyl group
- a halogen-substituted alkylcarbonyl group includes a trifluoroacetyl group
- Alkoxycarbonyl means a group in which the above “alkoxy” is substituted on carbonyl, for example, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyloxyreboninole, n-butoxycanolebonyl, i-Butoxycanolebonil, sec-butoxycanoleboninole, tert-butoxycanoleboninole, n-pentynoleoxycanoleboninole, n_hexynoleoxycarbonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl, etc.
- methoxycarbonyl, ethoxycarbonyl and the like are preferable.
- substituent of “optionally substituted carbamoyl” examples include alkyl (eg, methyl, ethyl, n-propyl, i-propyl, etc.), and acyl (eg, honolemil, acetyl, propionyl, benzoyl, etc.). No. The nitrogen atom of the carbamoyl group may be mono- or di-substituted with these substituents. As “substituted or substituted, carbamoyl”, carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl and the like are preferable.
- alkyl portion of “alkylsulfiel” has the same meaning as the above “alkyl”, and examples of “alkylsulfininole” include methanesulfiel, ethanesulfinyl and the like.
- alkyl part of “alkylsulfonyl” has the same meaning as the above “alkyl”.
- Examples of “alkylsulfonyl” include methanesulfonyl, ethanesulfonyl and the like.
- alkylsulfonyl moiety of “alkylsulfonyloxy” has the same meaning as the above “alkylsulfonyl”, and examples of “alkylsulfonyloxy” include methanesulfonyloxy, ethanesulfonyloxy and the like.
- aryl Optionally substituted aryl, “optionally substituted heteroaryl”, “optionally substituted non-aromatic carbocycle”, “optionally substituted non-aromatic heterocycle”, “Substituted, substituted, non-aromatic heterocyclic group", “substituted, substituted, aryloxy” or “substituted, substituted, arylalkyloxy” When it has a group, it may be substituted at any position by 114 identical or different substituents.
- substituent for example, hydroxy, carboxy, halogen atom (fluorine atom, chlorine atom, bromine atom, iodine atom), haloalkyl (for example, CF
- alkyl eg, methinole, ethyl, isopropyl, tert-butyl, etc.
- alkenyl eg, Bier
- formyl acyl (eg, acetyl, propionyl, butyryl, pivaloyl, benzoyl, pyridinecarbonyl, cyclopentanecarbonyl) , Cyclohexanecarbonyl, etc.)
- alkynyl eg, ethynyl
- cycloalkyl eg, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
- alkoxy eg, methoxy, ethoxy, propoxy, butoxy, etc.
- alkoxycarbonyl Eg, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.
- non-aromatic carbocycle in “R 2 and R 3 may form a 5- to 8-membered non-aromatic carbocycle containing adjacent carbon atoms” include the following groups.
- IT and IT shown below are preferably 5- or 6-membered cycloalkanes containing adjacent carbon atoms.
- (R 1 ) represents (la) a hydrogen atom, a halogen atom, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, optionally substituted amino, cyano or alkoxycarbonylalkoxy, (lb) a hydrogen atom, halogen Atom, alkyl, alkoxy, substituted or unsubstituted amino, cyano or alkoxycarbonylalkoxy, (Ic) hydrogen atom, halogen atom, optionally substituted amino, cyano or alkoxycarbonylalkoxy;
- R 2 is (Id) C2_C4 alkyl or C2-C4 alkenyl, (Ie) C2-C4 alkyl.
- R 3 is, (If) C2_C4 alkyl or C2-C4 alkenyl, (Ig) C2-C4 alkyl.
- R 4 is (Ih) Cl—C8 alkyl or CI—C6 alkoxy; (Ii) CI—C8 alkyl.
- X is (Ij) an oxygen atom or a sulfur atom.
- W is (Ik) substituted or unsubstituted, a hetero atom may be intervened, C2-C6 alkylene or May be substituted, may or may not be substituted with a hetero atom, C2-C4 alkenylene, (II) may be substituted with a C3-C6 alkylene or heteroatom, C3-C4 alkenylene, (Im) C3-C6 alkylene, (In) a heteroatom may be interposed, C3_C4 alkenylene.
- a preferred group of compounds represented by the general formula (I) includes [(R 1 ), R 2 , R 3 , R 4 , X
- (R 1 ) is (Ila) a hydrogen atom, a halogen atom, an alkyl, an alkoxy, an optionally substituted resamino, cyano or alkoxycarbonylalkoxy, (lib) a hydrogen atom, a halogen atom, an optionally substituted Amino, cyano or alkoxycarbonylalkoxy.
- R 2 is (IIc) C2_C4 alkyl.
- R 3 is (IId) C2_C4 alkyl.
- R 4 is (Ile) Cl—C6 alkyl, (Ilf) CI—C2 alkyl.
- X is (Ilg) an oxygen atom or a sulfur atom, (Ilh) an oxygen atom, and (IK) a sulfur atom.
- R 2 and R 3 comprises adjacent carbon atoms, (Ilj) 5- 6 membered cycloalkane, (Ilk) 6-membered cycloalkane.
- (R 1 ) is (Ilia) a hydrogen atom, a halogen atom, an alkyl, an alkoxy, an optionally substituted reamino, cyano or alkoxycarbonylalkoxy, (Illb) a hydrogen atom, a halogen atom, an optionally substituted , Cyano or alkoxycarbonylalkoxy.
- R 2 is (IIIc) C2-C4 alkyl.
- R 3 is (IIId) C2_C4 alkyl.
- R 4 is (Ille) Cl—C6 alkyl, (Illf) CI—C2 alkyl.
- X is (Illg) oxygen atom or sulfur atom, (Illh) oxygen atom, (Illi) sulfur atom.
- R 2 and R 3 include adjacent carbon atoms, (Illj) 5- to 6-membered cycloalkane, (IIIk) 6-membered cycloalkane.
- Z is (III1) CH CH CH one or Cti CH CH CH one, (Illm) -CH CH
- a preferred group of compounds represented by the general formula (III) includes [(R 1 ), R 2 , R 3 , R 4 , X, Z]
- the compound according to the present invention can be produced by the following steps. [Formula 7]
- R 2 and R 3 are the same or different and are C2-C4 alkyl, C2-C4 alkenyl, CI-C4 Coxy C1-C4 alkyl, optionally substituted amino C1-C4 alkyl or C3-C6 cycloalkyl C1-C4 alkyl; or
- R 2 and R 3 may form a 5-8 membered non-aromatic carbocyclic ring or a 5-8 membered non-aromatic heterocyclic ring containing adjacent carbon atoms;
- R 4 is C1-C6 alkyl, hydroxyalkyl optionally protected by a protecting group, (substituted, optionally, amino) alkyl or C1-C6 alkoxy C1-C6 alkyl;
- R 5 is the same or different and is an alkyl, an alkoxy, an alkylthio, an optionally substituted amino group which is protected by an optionally substituted amino group, Aryloxy, optionally substituted aralkyloxy, cycloalkyl, halogen atom, hydroxy protected with a protecting group, nitro, haloalkyl, haloalkoxy, optionally substituted rubamoyl, protected with a protecting group Carboxy, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, alkoxyalkyl, alkylthioalkyl, optionally substituted aminoalkyl, alkoximinoalkyl, alkoxyalkoxy, alkylthioalkoxy, alkoxycarbonylalkoxy, carboxyalkoxy Alkylsulfonyloxy, optionally substituted heteroaryl, optionally substituted non-aromatic heterocyclic group, cyanoalkoxy, or formula:
- X is an oxygen atom or a sulfur atom
- W is a substituted or unsubstituted heteroatom; a C2-C6 alkylene; an optionally substituted heteroatom C2-C4 alkenylene; n is 0 — Integer of 7) 1st step
- the method for converting an amino group into an isothiocyanate includes the following two methods: (1) a method in which a compound such as ammonia (NH, NH ⁇ H) / triethylamine (EtN) is used in the presence of a base;
- a base 1.0-1.5 equivalents
- carbon disulfide 1.0-1.5 equivalents
- an aprotic solvent for example, getyl ether, Stir for 0.5 hours to 10 hours in tetrahydrofuran, dimethylolenolemamide, benzene, toluene, dichloromethane, chloroform, etc.
- ethyl ethyl carbonate 1.0-1.5 equivalents
- triethylamine 1.0-1.5 equivalents
- the reaction temperature is preferably from 0 ° C to 100 ° C, particularly preferably from 0 ° C to room temperature.
- thiophosgene (1.0-1.5 equivalents) is added to the compound (IV), and an aprotic solvent (for example, getyl ether, tetrahydrofuran, dimethinolehonoleamide, benzene, toluene, Stir for 0.5 hours to 10 hours in dichloromethane, chloroform, etc.).
- the reaction temperature is preferably from 0 ° C to 100 ° C, particularly preferably from 0 ° C to room temperature.
- reaction temperature is preferably from 0 ° C to 100 ° C, particularly preferably from 0 ° C to room temperature.
- This step can be performed in an aprotic solvent (for example, getyl ether, tetrahydrofuran, dimethyl olenolemamide, benzene, toluene, dichloromethane, chloroform). Wear.
- an aprotic solvent for example, getyl ether, tetrahydrofuran, dimethyl olenolemamide, benzene, toluene, dichloromethane, chloroform.
- the reaction temperature is preferably from 0 ° C to 100 ° C, particularly preferably from o ° C to room temperature.
- the reaction time is preferably from 0.5 hours to 10 hours.
- NH—CH C (R 2 R 3 ) CH— ⁇ H can be used in an amount of 1.0 to 1.5 equivalents based on compound (V).
- NH—CH C (R 2 R 3 ) CH— ⁇ H includes 3-amino_2,2-getylpropanol, 3
- an aprotic solvent e.g., getyl ether, tetrahydrofuran, dimethylformamide, benzene, toluene, dichloromethane, chloroform, etc.
- aprotic solvent e.g., getyl ether, tetrahydrofuran, dimethylformamide, benzene, toluene, dichloromethane, chloroform, etc.
- carbon tetrachloride and triphenylphosphine (PhP) may be used in an amount of 1.0 to 1.5 equivalents to the compound (VI).
- the mixture may be heated and refluxed in concentrated hydrochloric acid for 0.5 hours to 10 hours.
- the Hal is halo (Representing a gen atom).
- the reaction can be carried out in accordance with the usual N-acinolelation conditions.
- an aprotic solvent eg, dimethyl ether, tetrahydrofuran, dimethylformamide, benzene, toluene, dichloromethane, chloroform, etc.
- the reaction may be performed at 0 ° C and 100 ° C for 0.5 hours to 10 hours.
- CS carbon disulfide
- a base eg, sodium hydride, etc.
- an alkyl halide eg, methane, eodoethane, etc.
- an alkoxyalkyl halide eg, chloromethyl methyl ether, etc.
- an aprotic solvent for example, getyl ether, tetrahydrofuran, dimethylformamide, benzene, toluene, dichloromethane, chloroform, etc.
- the reaction proceeds at room temperature of o ° c.
- Alkylation is the reaction of an alkyl halide (eg, methane, eodoethane, etc.) or an (alkoxycarbonyl) alkyl halide (eg, tert-butoxycarbonylmethyl bromide) in the presence of a base (eg, sodium hydride).
- a base eg, sodium hydride
- an aprotic solvent eg, dimethyl ether, tetrahydrofuran, dimethylformamide, benzene, toluene, dichloromethane, chloroform, etc.
- the reaction proceeds at 0 ° C. to room temperature. I do.
- a in formula (I) is benzothiadiazole-41-yl, it can be manufactured by the following steps. In each step, a method similar to each step in the production of the above formulas (IV) to (lb) can be used.
- Prodrugs are compounds that become pharmaceutically active compounds of the present invention in vivo under physiological conditions. Methods for selecting and producing suitable prodrug derivatives are described, for example, in Design of Prodrugs, Elsevier, Amsterdam 1985.
- the prodrug of the compound according to the present invention can be produced by introducing a leaving group into a substituent (for example, amino-containing hydroxy or the like) on the A ring to which a leaving group can be introduced.
- amino group prodrugs examples include olebamates (eg, methyl carbamate, cyclopropylmethyl carbamate, t-butyl carbamate, benzyl carbamate, etc.), amides (eg, honolemamide, acetamamide, etc.), N-alkyl (eg, , N-arylamine, N-methoxymethylamine and the like.
- hydroxy group prodrugs include ethers (eg, methoxymethyl ether, methoxyethoxymethyl ether) and esters (eg, acetate, pivaloate, benzoate, etc.).
- basic salts include, for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; trimethylamine salt; Aliphatic amine salts such as triethylamine salt, dicyclohexylamine salt, ethanolanolamine salt, diethanolamine salt, triethanolamine salt, brocaine salt; aralkylamine salts such as N, N_dibenzylethylenediamine; pyridine salt, picoline salt , Quinoline salts, isoquinoline salts and other heterocyclic aromatic amine salts; tetramethylammonium Quaternary ammonium salts such as salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammonium salt, methyltrioctylammonium salt, tetrabutylam
- a basic amino acid salt such as an arginine salt and a lysine salt
- the acidic salt include inorganic salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, and perchlorate; acetate, propionate, lactate, and maleate.
- Organic acid salts such as, fumarate, tartrate, malate, citrate, and ascorbate; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, and p-toluenesulfonate Acidic amino acids such as aspartate and gnoretamate;
- the solvate means a solvate of the compound represented by the formula (1), the formula (II) or the formula (III), a prodrug thereof, or a pharmaceutically acceptable salt thereof. , Disolvates, monohydrates, dihydrates and the like.
- the compound of the present invention can be used for the purpose of treating or preventing a disease involving a cannapinoid receptor agonist.
- Nature, 1993, Vol. 365, p. 61-65 states that the cannabinoid receptor agonist has anti-inflammatory and analgesic effects, and that the cannabinoid receptor agonist has an ioumal of Cannabis Therapeutics.
- 2002, Vol. 1, No. 1, p. 59-71 states that cannabinoid receptor agonists have a bronchodilator effect and WO 03/035109 pamphlet states that they have an antipruritic effect. Let's do it.
- the compound of the present invention comprises an anti-inflammatory agent, an anti-allergic agent, an analgesic agent, a therapeutic agent for pain (a therapeutic agent for invasive pain, a therapeutic agent for neuropathic pain, a therapeutic agent for psychogenic pain, a therapeutic agent for acute pain, Pain treatment), immunodeficiency, immunosuppressant, immunomodulator, autoimmune disease, rheumatoid arthritis, multiple sclerosis, airway inflammatory cell infiltration inhibitor, airway hypersensitivity It can be used as a hypertension inhibitor, a bronchodilator, a mucus secretion inhibitor, an antipruritic agent, and the like.
- the pharmaceutical composition containing the compound of the present invention can take a dosage form for oral and parenteral administration. That is, tablets, capsules, granules, powders, syrups and the like
- Parenteral preparations such as preparations for oral administration, solutions or suspensions for injection such as intravenous injection, intramuscular injection, and subcutaneous injection, preparations for transdermal administration such as inhalants, eye drops, nasal drops, suppositories, and ointments It can also be a preparation for administration.
- preparations can be produced using suitable carriers, excipients, solvents, bases and the like known to those skilled in the art.
- suitable carriers e.g., excipients, solvents, bases and the like known to those skilled in the art.
- the active ingredient and auxiliary ingredients are compressed or molded together.
- Auxiliary ingredients include pharmaceutically acceptable excipients, such as binders (eg, corn starch), fillers (eg, ratatose, microcrystalline cellulose, etc.), disintegrants (eg, starch glycolic acid). Sodium) or a lubricant (for example, magnesium stearate). Tablets may be coated as appropriate.
- suspending agents eg, methyl cellulose
- emulsifiers eg, lecithin
- preservatives e.g., preservatives and the like
- an injectable preparation it may be in the form of a solution, a suspension or an oily or aqueous emulsion, which may contain a suspension stabilizer or a dispersant.
- an inhalant it is used as a liquid compatible with inhalers, and when used as eye drops, it is used as a liquid or suspending agent.
- the dose of the compound of the present invention varies depending on the administration form, the patient's symptoms, age, weight, sex, and the concomitant drug (if any), etc., and is ultimately left to the judgment of a physician.
- 0.01-100 mg preferably 0.01-10 mg, more preferably 0.1-10 mg / day / kg body weight per day
- 0.001-100 mg / day preferably 0.001-lmg / kg body weight / day.
- More preferably 0.01 to lmg. This may be administered in 1 to 4 divided doses.
- N_ (1-naphthyl) -N '_ (3-hydroxy-2,2_pentamethylenepropyl) thio Tetrachloride (69.22 g) was added to a mixture of crude oleoresin, triphenylphosphine (59.02 g) and acetonitrile (300 mL) under ice-cooling for 20 minutes, and the mixture was stirred at room temperature for 1 hour. Potassium carbonate (31.10 g) was added under ice cooling, and the mixture was stirred at room temperature for 1 hour. Ice water (400 mL) and ethyl acetate (300 mL) were added to the reaction mixture, which was crystallized.
- test examples of the compound of the present invention are shown below.
- a membrane fraction of CHO cells in which CB1 or CB2 receptor was stably expressed was used. Prepared membrane sample and test compound, and 38,000 dpm of [ 3 H] CP55940 (final concentration 0.5 nM: manufactured by PerkinElmer Life & Analytical Sciences) in Atsushi buffer (50 mM Tris-HCl containing 0.5% bovine serum albumin) Incubation was performed at 25 ° C. for 2 hours in a buffer solution (pH 7.4), 1 mM EDTA, and 3 mM MgC12).
- test compound was added to the CHO cells expressing the human CB1 or CB2 receptor, the mixture was incubated for 15 minutes, and then forskolin (final concentration: 4 ⁇ ⁇ , SIGMA) was added, and the mixture was incubated for 20 minutes. After adding IN HC1 to stop the reaction, the amount of cAMP in the supernatant was measured using a Cyclic AMP kit (CIS bio international). The cAMP production due to forskolin stimulation was defined as 100% of that of no forskolin stimulation, and the concentration (IC value) of the test compound showing a 50% inhibitory effect was determined.
- ICR male mice (5 weeks old) were used to examine the inhibitory effect of the compound of the present invention on formalin noxious stimulation.
- the test compound was dissolved in sesame oil and orally administered to mice 2 hours before formalin administration, and then formalin (2%, 20 L) was subcutaneously administered to the right hind limb.
- measurement was performed for 30 minutes after formalin administration, and divided into 5 minutes immediately after formalin administration (the first phase) and 20 minutes from 10 to 30 minutes (the second phase).
- the pain intensity was determined by measuring the inhibitory effect of the test compound using the total time of licking and biting actions on the right hind limb as an index, and calculating the ED value.
- the ED value of I-123 was 0.54 mg / kg, indicating a strong itch suppression effect.
- acetylcholine (ACh) was intravenously administered to guinea pigs sequentially at a low concentration every 5 minutes, and the airway constriction response that occurred immediately after was administered by a method modified from the Konzett & Rossler method. It was measured.
- active ingredient means a compound of the present invention, its tautomers, their prodrugs, their pharmaceutically acceptable salts or their solvates.
- Hard gelatin capsules are made using the following ingredients:
- Tablets are prepared using the following ingredients:
- Propellant 22 (chlorodifluoromethane) 74.00
- the active ingredient and ethanol are mixed, the mixture is added to a portion of the propellant 22, cooled to -30 ° C and transferred to a filling device. The required amount is then supplied to a stainless steel container and diluted with the remaining propellant. Attach the bubble unit to the container.
- a tablet containing 60 mg of the active ingredient is prepared as follows:
- the active ingredient, starch, and cellulose are sifted through a No. 45 mesh US sieve and mixed thoroughly.
- the aqueous solution containing polyvinylpyrrolidone is mixed with the obtained powder, and the mixture is then passed through a No. 14 mesh US sieve.
- the granules thus obtained are dried at 50 ° C and passed through a No. 18 mesh U.S. sieve.
- Sodium carboxymethyl starch, magnesium stearate, and talc that have been previously passed through a No. 60 mesh U.S. sieve are added to the granules, mixed, and compressed using a tablet machine to give tablets each weighing 150 mg.
- Capsules containing 80 mg of active ingredient are prepared as follows:
- Suppositories containing 225 mg of the active ingredient are prepared as follows:
- the active ingredient is passed through a No. 60 mesh US sieve and suspended in the saturated fatty acid glyceride that has been previously heated to a minimum and melted. Then, mix this mixture into an apparent 2g mold And cool.
- Suspensions containing 50 mg of active ingredient are prepared as follows:
- An intravenous formulation is prepared as follows:
- Solutions of the above components are typically administered intravenously to a patient at a rate of 1 ml per minute.
- 2_naphthylimino 1,3_thiazine derivatives having cannapinoid receptor agonist action show an analgesic effect, a pain treatment effect, an antipruritic effect, or a bronchodilator effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/568,963 US7482339B2 (en) | 2003-08-26 | 2004-08-24 | 2-Naphthylimino-1,3-thiazine derivative |
EP04772047A EP1659117A4 (en) | 2003-08-26 | 2004-08-24 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE |
CN2004800291514A CN1863784B (zh) | 2003-08-26 | 2004-08-24 | 2-萘基亚氨基-1,3-噻嗪衍生物 |
JP2005513826A JP4702840B2 (ja) | 2003-08-26 | 2004-08-24 | 2−ナフチルイミノ−1,3−チアジン誘導体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-300952 | 2003-08-26 | ||
JP2003300952 | 2003-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005026138A1 true WO2005026138A1 (ja) | 2005-03-24 |
Family
ID=34308385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012086 WO2005026138A1 (ja) | 2003-08-26 | 2004-08-24 | 2−ナフチルイミノ−1,3−チアジン誘導体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7482339B2 (ja) |
EP (1) | EP1659117A4 (ja) |
JP (1) | JP4702840B2 (ja) |
CN (1) | CN1863784B (ja) |
TW (1) | TW200508211A (ja) |
WO (1) | WO2005026138A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080287A1 (ja) * | 2005-01-25 | 2006-08-03 | Shionogi & Co., Ltd. | 2-アゾリルイミノ-1,3-チアジン誘導体 |
WO2006129609A1 (ja) * | 2005-05-30 | 2006-12-07 | Shionogi & Co., Ltd. | 2-ナフチルイミノ-5,5-ジ置換-1,3-チアジン誘導体 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6877300A (en) * | 1999-09-14 | 2001-04-17 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019807A1 (fr) * | 1999-09-14 | 2001-03-22 | Shionogi & Co., Ltd. | Derives de 2-imino-1,3-thiazine |
WO2002072562A1 (fr) * | 2001-03-08 | 2002-09-19 | Shionogi & Co., Ltd. | Preparation medicinale contenant un derive de 1,3-thiazine |
WO2003035109A1 (fr) * | 2001-10-22 | 2003-05-01 | Santen Pharmaceutical Co., Ltd. | Remedes contre le prurit |
WO2003070277A1 (fr) * | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antiprurigineux |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1618697A (en) | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
JP2001516361A (ja) | 1997-03-18 | 2001-09-25 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体作動薬 |
AU8127998A (en) | 1997-07-11 | 1999-02-08 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
CA2433158C (en) | 2000-12-28 | 2011-05-10 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
-
2004
- 2004-08-23 TW TW093125304A patent/TW200508211A/zh unknown
- 2004-08-24 US US10/568,963 patent/US7482339B2/en not_active Expired - Fee Related
- 2004-08-24 JP JP2005513826A patent/JP4702840B2/ja not_active Expired - Fee Related
- 2004-08-24 WO PCT/JP2004/012086 patent/WO2005026138A1/ja active Application Filing
- 2004-08-24 CN CN2004800291514A patent/CN1863784B/zh not_active Expired - Fee Related
- 2004-08-24 EP EP04772047A patent/EP1659117A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019807A1 (fr) * | 1999-09-14 | 2001-03-22 | Shionogi & Co., Ltd. | Derives de 2-imino-1,3-thiazine |
WO2002072562A1 (fr) * | 2001-03-08 | 2002-09-19 | Shionogi & Co., Ltd. | Preparation medicinale contenant un derive de 1,3-thiazine |
WO2003035109A1 (fr) * | 2001-10-22 | 2003-05-01 | Santen Pharmaceutical Co., Ltd. | Remedes contre le prurit |
WO2003070277A1 (fr) * | 2002-02-19 | 2003-08-28 | Shionogi & Co., Ltd. | Antiprurigineux |
Non-Patent Citations (2)
Title |
---|
FRIDE E. ET AL.: "Cannabinoids and cystic fibrosis: a novel approach to etiology and therapy", J. CANNABIS THER., vol. 2, no. 1, 2002, pages 59 - 71, XP002983306 * |
See also references of EP1659117A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080287A1 (ja) * | 2005-01-25 | 2006-08-03 | Shionogi & Co., Ltd. | 2-アゾリルイミノ-1,3-チアジン誘導体 |
WO2006129609A1 (ja) * | 2005-05-30 | 2006-12-07 | Shionogi & Co., Ltd. | 2-ナフチルイミノ-5,5-ジ置換-1,3-チアジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005026138A1 (ja) | 2006-11-16 |
JP4702840B2 (ja) | 2011-06-15 |
US7482339B2 (en) | 2009-01-27 |
CN1863784B (zh) | 2010-11-17 |
CN1863784A (zh) | 2006-11-15 |
US20060281738A1 (en) | 2006-12-14 |
EP1659117A4 (en) | 2008-11-19 |
TW200508211A (en) | 2005-03-01 |
EP1659117A1 (en) | 2006-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3936189B2 (ja) | 2−イミノ−1,3−チアジン誘導体 | |
JP5605844B2 (ja) | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 | |
EP1790638B1 (en) | Carbamoylpyridone derivative having hiv integrase inhibitory activity | |
RU2392271C2 (ru) | Производные 3-карбамоил-2-пиридона | |
WO2009133834A1 (ja) | 血管内皮リパーゼ阻害活性を有するケトアミド誘導体 | |
JP5207382B2 (ja) | ウレア誘導体 | |
JP6372891B2 (ja) | Ampk活性化作用を有する5−オキシベンズイミダゾールおよび5−オキシアザベンズイミダゾール誘導体 | |
AU2008252185A1 (en) | Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type I inhibitory activity | |
JPWO2016068099A1 (ja) | Ampk活性化作用を有する複素環誘導体 | |
WO2014069426A1 (ja) | Ampk活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体 | |
EP2141154A1 (en) | Oxazolidinone derivative having inhibitory activity on 11 -hydroxysteroid dehydrogenase type i | |
JP2004244320A (ja) | 含窒素複素環抗ウイルス剤 | |
WO2012081563A1 (ja) | 血管内皮リパーゼ阻害活性を有するベンゾチアゾールおよびアザベンゾチアゾール誘導体 | |
WO2012173099A1 (ja) | 血管内皮リパーゼ阻害活性を有するアミノ誘導体 | |
JP4188694B2 (ja) | 1,3−チアジン誘導体を含有する医薬組成物 | |
WO2005026138A1 (ja) | 2−ナフチルイミノ−1,3−チアジン誘導体 | |
JPWO2006129609A1 (ja) | 2−ナフチルイミノ−5,5−ジ置換−1,3−チアジン誘導体 | |
JP2013014548A (ja) | アシルスルホンアミド誘導体 | |
JPWO2005016351A1 (ja) | カンナビノイド受容体アゴニストの新規用途 | |
JP4929500B2 (ja) | 新規ベンゾジアゼピン類 | |
WO2017094743A1 (ja) | I型11βヒドロキシステロイド脱水素酵素阻害活性を有する医薬組成物 | |
JPWO2006080284A1 (ja) | 2−置換イミノ−1,3−オキサジン誘導体 | |
JPWO2006080287A1 (ja) | 2−アゾリルイミノ−1,3−チアジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480029151.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513826 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006281738 Country of ref document: US Ref document number: 10568963 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004772047 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004772047 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10568963 Country of ref document: US |